Drug discovery and development, a risky and costly process that usually takes over a decade, is being revolutionized by three technologies – artificial intelligence (AI), organ-on-a-chip (OOC), and digital twins. AI is transforming the process from identification to compound design to predictions, demonstrating significant time and cost savings. OOC provides a more accurate alternative to animal testing by mimicking human organ functions. Lastly, the use of digital twins allows for a more patient-centric approach to clinical trials by virtually replicating patient profiles. These technologies could speed up the drug discovery process, increase success rates, and reduce costs.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
